Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy

This session explores how cutting-edge innovation in cell and gene therapy can successfully transition from discovery to clinical application. Featuring Landmark Bio, the presentation highlights a purpose-built approach to overcoming the operational and technical challenges that often slow progress in advanced therapy development. By integrating process development, analytical capabilities, and flexible GMP manufacturing within a single platform, Landmark Bio aims to streamline workflows and reduce friction at critical milestones. Attendees will gain insight into how this translational CDMO supports early clinical programs while enabling efficient scale-up for complex modalities, including cell and gene therapies. The session underscores the importance of reliability, coordination, and adaptability in bringing breakthrough science closer to patients, positioning Landmark Bio as a key partner in accelerating the path from innovation to real-world therapeutic impact.